Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
BMC Infect Dis ; 22(1): 682, 2022 Aug 09.
Article in English | MEDLINE | ID: covidwho-2214535

ABSTRACT

BACKGROUND: Immunization against the coronavirus disease 2019 (COVID-19) began in January 2021 in Iran; nonetheless, due to a lack of vaccination among children under 12, this age group is still at risk of SARS-CoV-2 infection and its complications. CASE PRESENTATION: SARS-CoV-2 infection was diagnosed in a 6-year-old girl who had previously been healthy but had developed a fever and pancytopenia. The bone marrow aspiration/biopsy demonstrated just hypocellular marrow without signs of leukemia. She was worked up for primary and secondary causes of pancytopenia. Except for a repeated reactive HIV antibody/Ag P24 assay, all test results were inconclusive. After a thorough diagnostic investigation, the cross-reactivity of the HIV antibody/Ag P24 test with SARS-CoV-2 antibodies was confirmed. The patient did not develop any COVID-19-related signs and symptoms, but she did get a severe invasive fungal infection and neutropenic enterocolitis. She died as a result of disseminated intravascular coagulopathy. CONCLUSION: It is critical to recognize children infected with SARS-CoV-2 who exhibit atypical clinical manifestations of COVID-19, such as persistent pancytopenia. SARS-CoV-2 infection can cause severe and deadly consequences in children; thus, pediatricians should be aware of COVID-19's unusual signs and symptoms mimicking other conditions such as aplastic anemia.


Subject(s)
Anemia, Aplastic , COVID-19 , Enterocolitis, Neutropenic , HIV Infections , Invasive Fungal Infections , Pancytopenia , Anemia, Aplastic/etiology , Bone Marrow/pathology , COVID-19/complications , Child , Enterocolitis, Neutropenic/complications , Female , HIV Infections/complications , Humans , Invasive Fungal Infections/complications , Pancytopenia/diagnosis , Pancytopenia/etiology , SARS-CoV-2
2.
Am J Case Rep ; 23: e937500, 2022 Sep 24.
Article in English | MEDLINE | ID: covidwho-2121397

ABSTRACT

BACKGROUND Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). While bone marrow (BM) involvement is common in lymphoma, primary bone marrow (PBM) DLBCL is extremely rare. We present a case of PBM DLBCL discovered in a patient with COVID-19. CASE REPORT An 80-year-old man presented with generalized abdominal pain, weight loss, fever, fatigue, anorexia, and watery diarrhea over a 3-month period. Physical examination was unremarkable. Laboratory workup revealed anemia, thrombocytopenia, and elevated inflammation markers. SARS-COV-2 PCR was positive, while blood cultures were negative. A rapid decline in the white blood cell count in the following days prompted a BM biopsy, confirming the diagnosis of PBM DLBCL. Computed tomography (CT) did not show thoracic or abdominal lymphadenopathy. The patient received packed red blood cell and platelet transfusions, granulocyte colony-stimulating factor (G-CSF) for pancytopenia, and empirical antibiotics for suspected infection. Due to active COVID-19 and advanced age, cytotoxic chemotherapy was delayed. Rituximab and prednisone were initiated on day 9, followed by an infusion reaction, which led to treatment discontinuation. He died 2 days later. CONCLUSIONS Diagnosing PBM malignancy is challenging, especially with coexisting infection. It is essential to suspect underlying BM malignancy in patients with clinical deterioration and worsening pancytopenia despite adequate treatment. The diagnosis of PBM DLBCL requires the absence of lymphadenopathy, and the presence of histologically confirmed DLBCL. Prompt management with combination chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with/without hematopoietic stem cell transplant can improve the prognosis.


Subject(s)
COVID-19 , Lymphadenopathy , Lymphoma, Large B-Cell, Diffuse , Pancytopenia , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow/pathology , COVID-19/complications , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Granulocyte Colony-Stimulating Factor/therapeutic use , Humans , Lymphadenopathy/pathology , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/therapy , Male , Pancytopenia/etiology , Prednisone/therapeutic use , Rituximab/therapeutic use , SARS-CoV-2 , Vincristine/therapeutic use
6.
BMC Geriatr ; 21(1): 178, 2021 03 12.
Article in English | MEDLINE | ID: covidwho-1133582

ABSTRACT

BACKGROUND: Pancytopenia, fever, and elevated D-dimer are significant clinical findings. The differential diagnosis includes hematological malignancies, severe coronavirus disease 2019 (COVID-19), tick-borne illnesses, and other etiologies. CASE PRESENTATION: We report the case of a 95-year-old woman who presented with high fever (103.6 °F), pancytopenia, and markedly elevated D-dimer (32.21 mg/L; reference range ≤ 0.95 mg/L) in late-autumn during the COVID-19 pandemic at a large academic institution. After remaining persistently febrile, a peripheral blood smear was ordered and revealed parasites consistent with Ehrlichia spp. Doxycycline monotherapy led to symptomatic improvement and resolution of her pancytopenia. During her hospital stay, a computed tomography angiogram of the chest revealed pulmonary emboli, and esophagogastroduodenoscopy uncovered arteriovenous malformations. After appropriate treatment, she was discharged on hospital day 7 and has since done well. CONCLUSIONS: Overall, our case offers a dramatic, unexpected presentation of ehrlichiosis in a nonagenarian. To our knowledge, this is the first report of concurrent ehrlichiosis and pulmonary embolus.


Subject(s)
COVID-19 , Ehrlichiosis , Pancytopenia , Aged, 80 and over , Ehrlichiosis/diagnosis , Ehrlichiosis/drug therapy , Female , Fibrin Fibrinogen Degradation Products , Humans , Pancytopenia/diagnosis , Pancytopenia/etiology , Pandemics , SARS-CoV-2
7.
Am J Med Genet A ; 185(6): 1854-1857, 2021 06.
Article in English | MEDLINE | ID: covidwho-1121487

ABSTRACT

The COVID-19 pandemic has affected the health and healthcare of individuals of all ages worldwide. There have been multiple reports and reviews documenting a milder effect and decreased morbidity and mortality in the pediatric population, but there have only been a small number of reports discussing the SARS-CoV-2 infection in the setting of an inborn error of metabolism (IEM). Here, we report two patients with underlying metabolic disorders, propionic acidemia and glutaric aciduria type 1, and discuss their clinical presentation, as well as their infectious and metabolic management. Our report demonstrates that individuals with an underlying IEM are at risk of metabolic decompensation in the setting of a COVID-19 infection. The SARS-CoV-2 virus does not appear to cause a more severe metabolic deterioration than is typical.


Subject(s)
Amino Acid Metabolism, Inborn Errors/complications , Brain Diseases, Metabolic/complications , COVID-19/complications , Glutaryl-CoA Dehydrogenase/deficiency , Propionic Acidemia/complications , SARS-CoV-2 , Acidosis/etiology , Acidosis/therapy , Acidosis, Lactic/etiology , Blood Component Transfusion , COVID-19/diagnosis , COVID-19 Nucleic Acid Testing , Combined Modality Therapy , Dietary Proteins/administration & dosage , Disease Management , Disease Susceptibility , Energy Intake , Enteral Nutrition , Female , Fluid Therapy , Glucose/administration & dosage , Glucose/adverse effects , Humans , Hyperammonemia/etiology , Hyperammonemia/therapy , Hyperglycemia/chemically induced , Hyperglycemia/drug therapy , Infant , Insulin/therapeutic use , Intensive Care Units, Pediatric , Oxygen Inhalation Therapy , Pancytopenia/etiology , Pancytopenia/therapy , Renal Dialysis , Systemic Inflammatory Response Syndrome/diagnosis
8.
Am J Emerg Med ; 45: 685.e1-685.e3, 2021 07.
Article in English | MEDLINE | ID: covidwho-1009248

ABSTRACT

Neutropenic enterocolitis is also known as typhlitis, is characterized by severe inflammation in the bowel loops. It is often seen in immunosuppressed patients, and it has high morbidity and mortality. Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory system and causes COVID-19 (Coronavirus Disease 2019), it may affect hematopoietic and gastrointestinal systems. Herein, we present a rare case of COVID-19-associated pancytopenia and typhlitis in a 60-year-old female who presented with abdominal pain. Contrast-enhanced abdominal computed tomography (CT) demonstrated the bowel wall thickening in the cecum and ascending colon compatible with enterocolitis. Moreover, the chest CT showed bilateral, peripheral, and multifocal ground-glass opacities, consistent with COVID-19 pneumonia. We also aimed to emphasize the laboratory, clinical, and CT findings of the patient.


Subject(s)
COVID-19/complications , Colon/diagnostic imaging , Lung/diagnostic imaging , Pancytopenia/etiology , Tomography, X-Ray Computed/methods , Typhlitis/etiology , COVID-19/diagnosis , COVID-19/epidemiology , Female , Humans , Middle Aged , Pancytopenia/diagnosis , Pandemics , SARS-CoV-2 , Typhlitis/diagnosis
10.
Isr Med Assoc J ; 22(8): 505-513, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-972915

ABSTRACT

BACKGROUND: In this review we described the values of commonly available HScore laboratory markers in patients with coronavirus-19 (COVID-19)-pneumonia associated cytokine storm syndrome (CPN-CSS) and compared results with those of other forms cytokine storm syndrome (O-CSS) to determine a pattern for CPN-CSS. Twelve CPN-CSS studies and six O-CSS studies were included. CPN-CSS typically obtained a single HScore value (e.g., aspartate transaminase > 30 U/L) while failing all other HScore criteria. A typical pattern for CPN-CSS was revealed when compared to O-CSS: lymphopenia vs. pancytopenia and increased vs. decreased fibrinogen. Findings, other than HScore commonly found in CPN-CSS studies, showed elevated lactate dehydrogenase, D-dimer, and C-reactive protein. Although CPN-CSS studies describe severely ill patients, the HScore markers are typically less toxic that O-CSS.


Subject(s)
COVID-19/blood , COVID-19/complications , Cytokine Release Syndrome/blood , Cytokine Release Syndrome/etiology , Pneumonia/blood , Pneumonia/virology , Aspartate Aminotransferases/blood , C-Reactive Protein/metabolism , Ferritins/blood , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/metabolism , Humans , L-Lactate Dehydrogenase/blood , Lymphohistiocytosis, Hemophagocytic/blood , Lymphohistiocytosis, Hemophagocytic/complications , Lymphopenia/virology , Pancytopenia/etiology , Patient Acuity , SARS-CoV-2
13.
J Vet Diagn Invest ; 32(4): 616-620, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-634158

ABSTRACT

Ferret systemic coronaviral disease (FSCD) is a well-established cause of mortality in domestic ferrets. We describe herein novel findings in a case of FSCD that was diagnosed and medically managed following virus detection by immunohistochemical (IHC) staining of surgical biopsy samples. Hematologic changes in this ferret suggested spread of the virus to the bone marrow, which was confirmed by IHC staining of a postmortem sample. Genotyping of the virus indicated that the virus grouped with alphacoronaviruses and was most closely related to ferret enteric coronavirus (FRECV) MSU-2. Our clinical case demonstrates that a FRECV MSU-2-like ferret coronavirus associated previously with the enteric pathotype may cause systemic disease, including bone marrow involvement causing persistent pancytopenia.


Subject(s)
Alphacoronavirus/isolation & purification , Coronavirus Infections/veterinary , Ferrets/virology , Pancytopenia/veterinary , Animals , Coronavirus Infections/virology , Pancytopenia/etiology
SELECTION OF CITATIONS
SEARCH DETAIL